Qubit Pharmaceuticals announces the appointment of Sara Dolcetti as Vice President Business Development

Press release

Paris (France), June 29, 2023 - Qubit Pharmaceuticals, a deeptech company specializing in drug discovery through simulation and molecular modeling accelerated by hybrid HPC and quantum computing, announces the recruitment of Sara Dolcetti as Vice President in charge of Business Development.

Sara Dolcetti joins Qubit Pharmaceuticals from Koninklijke Philips, where she led business and product development in oncology for the company's first SaaS platform. Her mission was to bring physicians and their patients the best cancer care, from early detection to molecular diagnostics, therapeutic recommendations and clinical trials, using AI and other approaches. She has established key partnerships leading to new product development and expansion into new geographies, including a joint venture in China. Prior to this role, she led Philips Group strategy and M&A initiatives, which helped drive innovation in the precision medicine and population health markets.

Previously, she worked at Analysis Group on product launches for biopharmaceutical companies and as a consultant at the Boston Consulting Group.

Sara holds a Master of Science (MSc) and a Master in Business Administration (MBA) from the Massachusetts Institute of Technology (MIT), as well as a Bachelor of Applied Science in Engineering from the University of Toronto, where she was a W.S. Wilson Scholar.

Sara Dolcetti appointed VP Business Development at Qubit Pharmaceuticals

Robert Marino , President of Qubit Pharmaceuticals comments: "We are extremely pleased to welcome Sara to Qubit Pharmaceuticals as VP of Business Development. In addition to her extensive experience and in-depth knowledge of the healthcare sector, it's her keen understanding of the challenges facing the pharmaceutical industry that has impressed us. Sara arrives just in time for the launch of our first partnerships, notably with the University of Sherbrooke's Institute of Pharmacology, selection for the French Tech 2030 program, and the maturation of some of our drug candidate discovery programs. We are confident that she will quickly become a key member of our team, particularly in promoting Qubit Pharmaceuticals in North America."

About Qubit Pharmaceuticals

Qubit Pharmaceuticals was founded in 2020 with the vision of co-developing new, safer and more effective medicines with pharmaceutical and biotech companies. Its software makes the most of existing and emerging supercomputers to model quantum effects at the microscopic level with maximum precision. The multidisciplinary team and founders are based in France at the Paris Santé Cochin incubator and in the USA in Boston. For more information, or to apply for a job with an ambitious team, visit www.qubit-pharmaceuticals.com

Press contacts

Ulysse Communication

Charles Courbet - [email protected] - +33 6.28.93.03.06

Nicolas Daniels - [email protected] - + 33 6.63.66.59.22